Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02147301 · ClinicalTrials.gov registry record · NA
TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve
A NA study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT02147301 is a NA study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 17 participants.
The verdict
NCT02147301, a NA study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
TACE is frequently offered to patients with baseline hepatic dysfunction with the purpose of diminishing hepatic tumor burden while patients await transplantation. Without this therapeutic measure, disease may progress beyond UNOS T2 criteria required for organ allocation. The purpose of the study is to determine whether transarterial chemoembolization using doxorubicin-eluting beads (DEB-TACE) can be used safely and effectively to treat patients with liver-only hepatocellular carcinoma (HCC) and baseline hepatic dysfunction.
Interventions
- DEVICE LC Bead
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-12-17 |
| Est. Completion | 2017-04-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02147301
The ClinicalTrials.gov registry entry for NCT02147301 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LC Bead is the first listed.
NCT02147301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02147301 about?
NCT02147301 is a clinical study titled "TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve". TACE is frequently offered to patients with baseline hepatic dysfunction with the purpose of diminishing hepatic tumor burden while patients await transplantation. Without this therapeutic measure, disease may progress beyond UNOS T2 criteria required for organ allocation. The purpose of the study ...
What is the current status of trial NCT02147301?
This trial is currently terminated. It is a NA study. The enrollment target is 17 participants. The study started on 2014-12-17. Estimated completion is 2017-04-05.
What interventions are being tested in trial NCT02147301?
The interventions under investigation include: LC Bead (DEVICE).
Who is sponsoring clinical trial NCT02147301?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.